Compare · ENTA vs NVS
ENTA vs NVS
Side-by-side comparison of Enanta Pharmaceuticals Inc. (ENTA) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENTA and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $305.69B, about 983.6x ENTA ($310.8M).
- ENTA has been more active in the news (9 items in the past 4 weeks vs 5 for NVS).
- Both have 25 recent analyst ratings on file.
- Company
- Enanta Pharmaceuticals Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $310.8M
- $305.69B
- 1M return
- -
- +6.01%
- 1Y return
- -
- +21.06%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 25
Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest ENTA
- SEC Form SCHEDULE 13G filed by Enanta Pharmaceuticals Inc.
- Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.
- Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
- SEC Form 8-K filed by Enanta Pharmaceuticals Inc.
- SEC Form 8-K filed by Enanta Pharmaceuticals Inc.
- Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
- Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank